Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Abstract Patients with rare solid tumors treated on early phase trials experience toxicities from their tumors and treatments. However, limited data exist to describe the detailed symptom burden suffered by these patients, particularly those with rare solid tumors treated with immunotherapy. We perf...

Full description

Bibliographic Details
Main Authors: Tito R. Mendoza, David S. Hong, Christine B. Peterson, Bettzy Stephen, Ecaterina Dumbrava, Shubbam Pant, Apostolia Maria Tsimberidou, Timothy Anthony Yap, Ajay Sheshadri, Mehmet Altan, Goldy George, Lilibeth Castillo, Enedelia Rodriguez, Jing Gong, Vivek Subbiah, Filip Janku, Siqing Fu, Sarina A. Piha-Paul, Jordi Rodon Ahnert, Daniel D. Karp, Charles Cleeland, Funda Meric-Bernstam, Aung Naing
Format: Article
Language:English
Published: Nature Portfolio 2022-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-16588-3

Internet

https://doi.org/10.1038/s41598-022-16588-3

Similar Items